NERV
Minerva Neurosciences Inc

9,275
Loading...
Loading...
News
all
press releases
Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Decline in Short Interest
Minerva Neurosciences, Inc. (NASDAQ:NERV Get Free Report) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 38,300 shares...
Ticker Report·1y ago
News Placeholder
More News
News Placeholder
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Globe Newswire·2y ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at StockNews.com
StockNews.com downgraded shares of Minerva Neurosciences (NASDAQ:NERV Free Report) from a hold rating to a sell rating in a research note published on Friday. Minerva Neurosciences Trading...
Zolmax·2y ago
News Placeholder
Minerva Neurosciences: Q4 Earnings Insights
read more...
Benzinga·2y ago
News Placeholder
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Globe Newswire·2y ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Raised to Hold at StockNews.com
StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV Free Report) from a sell rating to a hold rating in a research note released on Monday. Minerva Neurosciences Stock...
Zolmax·2y ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at StockNews.com
StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday. Minerva Neurosciences...
Ticker Report·2y ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com
Minerva Neurosciences (NASDAQ:NERV Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a research...
Zolmax·2y ago

Latest NERV News

View

Advertisement. Remove ads.

Advertisement. Remove ads.